55674-67-4

Basic information

• Product Name: BOC-D-THR-OH
• Synonyms: N-ALPHA-TERT-BUTOXYCARBONYL-D-THREONINE;N-ALPHA-T-BUTOXYCARBONYL-D-THREONINE;N-ALPHA-T-BOC-D-THREONINE;N-ALPHA-T-BOC-D-THREONINE / (2R,3S);N-TERT-BUTOXYCARBONYL-D-THREONINE;BOC-D-THR-OH;BOC-D-THREONINE;BOC-D-THR
• CAS NO: 55674-67-4
• Molecular Formula: C₉H₁₇NO₅
• Molecular Weight: 219.23
• Product Categories: Threonine [Thr, T];Boc-Amino Acids and Derivative;Amino Acids;Amino Acids (N-Protected);Biochemistry;Boc-Amino Acids
• Mol File: 55674-67-4.mol
• Article Data: 39

Chemical Properties

• Melting Point: 81 °C
• Boiling Point: 387.1oC at 760 mmHg
• Flash Point: 187.9oC
• Appearance: /Solid
• Density: 1.202g/cm3
• Vapor Pressure: 1.36E-07mmHg at 25°C
• Refractive Index: 9 ° (C=1, AcOH)
• Storage Temp.: Store at RT.
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: BOC-D-THR-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-D-THR-OH(55674-67-4)
• EPA Substance Registry System: BOC-D-THR-OH(55674-67-4)

Safety Data

• Hazardous Substances Data: 55674-67-4(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Uses

It is known to inhibit growth and cell wall synthesis of Mycobacterium smegmatis. Also used as a synthetic intermediate for the production of chiral antibiotics.

InChI:InChI=1/C9H17NO5/c1-5(11)6(7(12)13)10-8(14)15-9(2,3)4/h5-6,11H,1-4H3,(H,10,14)(H,12,13)/t5-,6-/m1/s1

Upstream product

• 24830-94-2 D-allo-threonine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 113525-91-0 (2S,3S)-methyl 2-[(tert-butoxycarbonyl)amino]-3-hydroxybutanoate 
• 72-19-5 DL-threonine 
• 632-20-2 D-Threonine 
• 72-19-5 rac-allo-threonine 
• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 924-49-2 DL-4-amino-3-hydroxybutyric acid 
• 909114-65-4 tert-butyl 4,6-dimethoxy-1,3,5-triazinyl carbonate 
• 1262723-05-6 tert-butyl (1S,2S)-1-((2-oxo-2-(pyren-3-yl)ethoxy)carbonyl)-2-hydroxypropylcarbamate 
• 28954-12-3 (2S,3S)-2-amino-3-hydroxybutanoic acid 
• 34619-03-9 tert-butyldicarbonate 

Downstream Products

• 436849-04-6 BOC-D-α-Thr-OBn 
• 742060-65-7 Boc-L-allo-Thr-OBn 
• 347191-37-1 Boc-L-aThr-L-Phe-L-Pro-Thz-OMe 
• 174698-98-7 [(1S,2S)-2-Hydroxy-1-((R)-1-phenyl-ethylcarbamoyl)-propyl]-carbamic acid tert-butyl ester 
• 1237534-95-0 (2S,3R)-2-methyl-4-oxo-3-oxetanylcarbamic acid tert-butyl ester 
• 1416468-80-8 tert-butyl [(2R,3S)-1-{4-[(4aS,8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl]piperidin-1-yl}-3-hydroxy-1-oxobutan-2-yl]carbamate 
• 1396972-31-8 (2R,3S)-2-(tert-butoxycarbonylamino)-3-methoxybutanoic acid 

Relevant articles and documents

KCNT1 INHIBITORS AND METHODS OF USE

The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

CYCLIC PEPTIDE ANTIBIOTICS

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

CYCLIC PEPTIDE ANTIBIOTICS

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.